827 related articles for article (PubMed ID: 25964225)
1. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis.
Mosli MH; Zou G; Garg SK; Feagan SG; MacDonald JK; Chande N; Sandborn WJ; Feagan BG
Am J Gastroenterol; 2015 Jun; 110(6):802-19; quiz 820. PubMed ID: 25964225
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
3. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
4. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.
Sipponen T; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
Inflamm Bowel Dis; 2008 Jan; 14(1):40-6. PubMed ID: 18022866
[TBL] [Abstract][Full Text] [Related]
5. Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease.
Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
Eur J Clin Invest; 2016 Oct; 46(10):825-32. PubMed ID: 27438629
[TBL] [Abstract][Full Text] [Related]
6. Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study.
Kwapisz L; Mosli M; Chande N; Yan B; Beaton M; Micsko J; Mennill PW; Barnett W; Bax K; Ponich T; Howard J; Tirolese A; Lannigan R; Gregor J
Saudi J Gastroenterol; 2015; 21(6):360-6. PubMed ID: 26655130
[TBL] [Abstract][Full Text] [Related]
7. Calprotectin or Lactoferrin: Do They Help.
Wright EK
Dig Dis; 2016; 34(1-2):98-104. PubMed ID: 26982329
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Fecal Inflammatory Markers in Crohn's Disease.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Keenan JI; Leach S; Burgess L; Aitchison A; Gorelik A; Liew D; Day AS; Gearry RB
Inflamm Bowel Dis; 2016 May; 22(5):1086-94. PubMed ID: 26818420
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.
Yang Z; Clark N; Park KT
Clin Gastroenterol Hepatol; 2014 Feb; 12(2):253-62.e2. PubMed ID: 23883663
[TBL] [Abstract][Full Text] [Related]
10. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis.
Rokkas T; Portincasa P; Koutroubakis IE
J Gastrointestin Liver Dis; 2018 Sep; 27(3):299-306. PubMed ID: 30240474
[TBL] [Abstract][Full Text] [Related]
11. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
[TBL] [Abstract][Full Text] [Related]
12. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
Jusué V; Chaparro M; Gisbert JP
Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
[TBL] [Abstract][Full Text] [Related]
14. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
Shimoyama T; Yamamoto T; Yoshiyama S; Nishikawa R; Umegae S
Inflamm Bowel Dis; 2023 Sep; 29(9):1399-1408. PubMed ID: 36334015
[TBL] [Abstract][Full Text] [Related]
15. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
[TBL] [Abstract][Full Text] [Related]
16. Disease monitoring in inflammatory bowel disease.
Chang S; Malter L; Hudesman D
World J Gastroenterol; 2015 Oct; 21(40):11246-59. PubMed ID: 26523100
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis.
Wang Y; Pei F; Wang X; Sun Z; Hu C; Dou H
Int J Clin Exp Pathol; 2015; 8(10):12319-32. PubMed ID: 26722419
[TBL] [Abstract][Full Text] [Related]
18. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control.
van Rheenen PF
Inflamm Bowel Dis; 2012 Nov; 18(11):2018-25. PubMed ID: 22275341
[TBL] [Abstract][Full Text] [Related]
19. Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial.
Langhorst J; Boone J; Lauche R; Rueffer A; Dobos G
J Crohns Colitis; 2016 Jul; 10(7):786-94. PubMed ID: 26874351
[TBL] [Abstract][Full Text] [Related]
20. AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis.
Singh S; Ananthakrishnan AN; Nguyen NH; Cohen BL; Velayos FS; Weiss JM; Sultan S; Siddique SM; Adler J; Chachu KA;
Gastroenterology; 2023 Mar; 164(3):344-372. PubMed ID: 36822736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
